Promoters of bafna pharmaceuticals have confirmed that no shares of the company were encumbered during the financial year ended March 31, 2026. The disclosures were submitted to the stock exchanges in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulatory filing ensures transparency regarding the pledging or hypothecation of promoter holdings.

Bafna Mahaveer Chand, a promoter of the company, declared on behalf of the Promoter and Promoter Group that no encumbrance of shares was made directly or indirectly in FY26. The confirmation was addressed to BSE Limited and the National Stock Exchange of India Limited. The company’s scrip codes are 532989 on the BSE and BAFNAPH on the NSE.

SRJR Lifesciences LLP, also identified as a promoter, submitted a separate declaration confirming that it did not create any encumbrance over the shares held by the firm during the same period. The disclosure was signed by Upendar Mekala Reddy, Designated Partner of SRJR Lifesciences LLP. The entity provided its LLPIN as AAR-4517.

The following table summarizes the key details of the disclosures:

The submissions were made to the exchanges on April 4, 2026, and April 1, 2026, respectively. Copies of the disclosures were also marked to the Audit Committee and the Company Secretary of Bafna Pharmaceuticals Limited. The company’s registered office is located in Chennai, Tamil Nadu.

Bafna Pharmaceuticals Limited accepted the retirement of Mr. Navin Kumar as an Independent Director upon the completion of his first term effective June 22, 2026. Consequently, he ceased to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee. The Board has reconstituted these committees effective June 23, 2026, to ensure continued compliance with applicable laws.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company informed the exchanges regarding the change. Mr. Navin Kumar's retirement took effect at the close of business hours on June 22, 2026. The company confirmed that despite this change, the composition of the Board and its Committees remains in compliance with regulatory requirements.

The reconstituted Audit Committee is chaired by Mr. Palamadai Krishnan Sundaresan. Members include Mrs. Ravichandran Chitra and Mr. Upendar Mekala Reddy. The Nomination and Remuneration Committee is also chaired by Mr. Palamadai Krishnan Sundaresan, with Mrs. Ravichandran Chitra and Mrs. Akila Chintalapati Raju serving as members.

The disclosures were made in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Mr. Navin Kumar's Director Identification Number (DIN) is 08778662.

Reconstituted Board Committees